Entresto (sacubitril/valsartan)
/ Novartis, ROVI Pharmaceuticals Laboratories, Otsuka
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
3970
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
June 27, 2025
REVERSE-LVH: Role of ARNi in Ventricular Remodeling in Hypertensive LVH
(clinicaltrials.gov)
- P2 | N=80 | Completed | Sponsor: National Heart Centre Singapore | Recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Dec 2023 ➔ Jun 2024
Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
June 27, 2025
ARNI-TZ: Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
(clinicaltrials.gov)
- P4 | N=238 | Not yet recruiting | Sponsor: Martin Rohacek | Initiation date: May 2025 ➔ Aug 2025
Trial initiation date • Cardiovascular • Congestive Heart Failure • Heart Failure
June 27, 2025
Renal Considerations in Sacubitril/Valsartan Uptitration for Heart Failure Patients.
(PubMed, Circ J)
- No abstract available
Journal • Cardiovascular • Congestive Heart Failure • Heart Failure
June 27, 2025
Renal Considerations in Sacubitril/Valsartan Uptitration for Heart Failure Patients - Reply.
(PubMed, Circ J)
- No abstract available
Journal • Cardiovascular • Congestive Heart Failure • Heart Failure
May 15, 2025
Additive benefits of dapagliflozin to sacubitril/valsartan in cardiometabolic age-related cardiac dysfunction involve endothelial oxidative defense and senescence
(ESC-WCC 2025)
- No abstract available
Cardiovascular • Congestive Heart Failure • Heart Failure
June 26, 2025
Heart Failure and Wide QRS: Clinical and Pharmacological Perspectives.
(PubMed, Biomedicines)
- "Currently, the cornerstone of VD therapy is cardiac resynchronization therapy (CRT). Our comprehensive review aims to analyze the effects of new molecules on QRS width and understand whether these molecules can provide benefits."
Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure
June 23, 2025
Insights into the Benefits of Reverse Remodeling from an Echocardiographic Pressure/Volume Loop Model in Patients With Heart Failure Treated With Sacubitril/Valsartan.
(PubMed, Am J Cardiol)
- "VA coupling was closely associated with LV efficiency at baseline (r = - 0.92) and after follow-up (r = - 0.74). In conclusion, LVRR that occurred in patients treated with S/V was associated with a better VA coupling and likely accounted for the beneficial effects on LV efficiency, namely SW/PVA."
Clinical • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure
June 26, 2025
The Effectiveness of Sacubitril/Valsartan in Systemic Sclerosis Patients with Heart Failure: A Retrospective Analysis.
(PubMed, J Clin Med)
- " This study showed that SV effectively improved cardiac symptoms and function in patients with SSc presenting with HFrEF. Further prospective studies are needed to confirm these findings and explore the role of SV in the treatment of other manifestations of SSc."
Journal • Retrospective data • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Hypotension • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis
June 20, 2025
The ENCHANTMENT HIV Study
(clinicaltrials.gov)
- P2 | N=50 | Active, not recruiting | Sponsor: Massachusetts General Hospital | Recruiting ➔ Active, not recruiting
Enrollment closed • Cardiovascular • Congestive Heart Failure • Heart Failure • Human Immunodeficiency Virus • Infectious Disease
May 15, 2025
Cardiac cGMP augmentation and hemodynamic improvement in heart failure with reduced ejection fraction: evidence from sacubitril/valsartan and vericiguat treatment
(ESC-WCC 2025)
- No abstract available
Cardiovascular • Congestive Heart Failure • Heart Failure
June 19, 2025
Effect of Neprilysin Inhibition on Plasma Proteins in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
(PubMed, JACC Heart Fail)
- No abstract available
Journal • Cardiovascular • Congestive Heart Failure • Heart Failure
June 26, 2025
Angiotensin Receptor Neprilysin Inhibitor in Heart Failure with Preserved Ejection Fraction and Secondary Mitral Regurgitation: Design and Rationale of the PRAISE-MR trial.
(PubMed, J Card Fail)
- "The PRAISE-MR trial will evaluate whether sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, is beneficial in patients with HFpEF and atrial FMR."
Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Hypotension • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases
June 16, 2025
CAESAR: Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure
(clinicaltrials.gov)
- P2/3 | N=515 | Completed | Sponsor: National Heart Institute, Egypt
New P2/3 trial • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease
May 15, 2025
Asymptomatic vs symptomatic hypotension with sacubitril/valsartan in patients with heart failure and reduced ejection fraction in real world practice
(ESC-WCC 2025)
- No abstract available
Clinical • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension
May 15, 2025
Cardiac left atrial evaluation and response in HFREF with sacubitril/valsartan: the CLEAR study.
(ESC-WCC 2025)
- No abstract available
Cardiovascular • Congestive Heart Failure • Heart Failure
May 15, 2025
Quantifying the impact of real-world evidence: the sacubitril/valsartan experience
(ESC-WCC 2025)
- No abstract available
Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure
June 24, 2025
Cardiac contractility modulation to enhance optimized medical therapy and improve cardiac remodeling in advanced heart failure: a case report.
(PubMed, Front Cardiovasc Med)
- "Due to hypotension (systolic blood pressure ≤90 mmHg), the patient was unable to tolerate full-dose GDMT, with sacubitril-valsartan limited to 25 mg twice daily, metoprolol succinate to 23.75 mg once daily, and spironolactone to 20 mg once daily. NT-proBNP levels also decreased from 6,553 pg/ml to within the normal range. This case suggests that CCM may serve as a promising strategy to address the issue of poor GDMT tolerance due to hypotension, thereby facilitating GDMT optimization and improving cardiac remodeling patients with HFrEF."
Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension
May 15, 2025
Sacubitril/valsartan in frail patients with acute myocardial infarction: real-world efficacy from a multicenter retrospective cohort study
(ESC-WCC 2025)
- No abstract available
Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Cardiovascular • Myocardial Infarction
June 26, 2025
Evaluation of the Effects of the Sodium-Glucose Cotransporter 2 Inhibitors and Sacubitril/Valsartan Combined Therapy in Patients with HFrEF: An Echocardiographic Study.
(PubMed, Int J Mol Sci)
- "Even the single introduction of additional iSGLT-2 in HFrEF patients on an otherwise optimized therapy resulted in a significant improvement in US and laboratory variables. The results of our study suggest implementing iSGLT-2 therapy as soon as possible, as the structural and functional cardiac improvements achieved by these drugs are achieved in the short term and maintained in the long term."
Journal • Observational data • Cardiovascular • Congestive Heart Failure • Heart Failure
May 15, 2025
The responses of B-type natriuretic peptide (BNP), mature BNP, proBNP, atrial natriuretic peptide, and N-terminal proBNP to sacubitril/valsartan differs between responders and non-responders
(ESC-WCC 2025)
- No abstract available
Cardiovascular
May 15, 2025
Reverse cardiac remodeling following with sacubitril/valsartan in heart failure: comparison between ischemic and non-ischemic etiology
(ESC-WCC 2025)
- No abstract available
Cardiovascular • Congestive Heart Failure • Heart Failure
May 15, 2025
Impact of sacubitril valsartan on sleep apnea in heart failure patients with reduced ejection fraction (SV-SLEEP): a systematic review and meta-analysis
(ESC-WCC 2025)
- No abstract available
Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure
May 15, 2025
Long term efficacy and safety of sacubitril/valsartan in chronic heart failure patients with reduced ejection fraction: a prospective real-world study.
(ESC-WCC 2025)
- No abstract available
Clinical • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure
June 26, 2025
SGLT2 inhibitors may increase creatinine clearance: data mining utilizing the FDA Adverse Event Report System database and pharmacokinetic study with rats.
(PubMed, Pharmacology)
- "These results suggest that SGLT2 inhibitors may increase renal clearance of creatinine or drugs."
Adverse events • Journal • PK/PD data • Preclinical
May 15, 2025
Effects of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and an eGFR below 30 ml/min/1.73 m2
(ESC-WCC 2025)
- No abstract available
Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure
1 to 25
Of
3970
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159